Cmg Pharmaceutical Co., Ltd. (058820)
Market Closed
14 Oct, 06:30 AM
KRX SM KRX SM Primary ₩
562. 00
0
0%
₩
213.63B Market Cap
- P/E Ratio
- Div Yield
689,859 Volume
- Eps
₩ 562
Previous Close Want to track 058820 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Upcoming 058820 split of 1:10 in 11 days (27 Oct 2026)
Summary
058820 closed yesterday higher at ₩562, an increase of 0% from Tuesday's close, completing a monthly decrease of -0.531% or -₩3. Over the past 12 months, 058820 stock lost -69.8174%.
058820 is not paying dividends to its shareholders.
Cmg Pharmaceutical Co., Ltd. has a scheduled stock split on Oct 27, 2026 for a 1:10 split ratio, meaning every 058820 investor will receive 1.0 shares for every 10.0 existing shares.
Cmg Pharmaceutical Co., Ltd. has completed 6 stock splits, with the recent split occurring on Jun 13, 2019.
The company's stock is traded on one exchange.
Cmg Pharmaceutical Co., Ltd. (058820) FAQ
What is the stock price today?
The current price is ₩562.00.
On which exchange is it traded?
Cmg Pharmaceutical Co., Ltd. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 058820.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 213.63B.
Has Cmg Pharmaceutical Co., Ltd. ever had a stock split?
Cmg Pharmaceutical Co., Ltd. had 6 splits and the recent split was on Jun 13, 2019.
Cmg Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | KRX SM Exchange | KR7058820002 ISIN |
| South Korea Country | 223 Employees | - Last Dividend | 27 Oct 2026 Last Split | - IPO Date |
Overview
CMG Pharmaceutical Co., Ltd., originally established as Skynewpharm Co Ltd in 2001 and rebranded in April 2013, is a pioneering pharmaceutical company based in Seoul, South Korea. Specializing in the development and distribution of oral thin film (OTF) pharmaceuticals, the company has carved out a significant niche in the South Korean pharmaceutical market. CMG Pharmaceutical is dedicated to improving patient convenience and efficacy of drug delivery through its innovative OTF technology. The company's collaboration with Handok Inc. for cancer treatment underscores its commitment to expanding its product range and addressing various medical conditions through strategic partnerships.
Products and Services
- Tadalafil OTF - Designed to treat erectile dysfunction, this product leverages the oral thin film technology to ensure rapid absorption and action, making it a convenient and discreet option for patients.
- Entecavir OTF - As part of CMG Pharmaceutical’s commitment to battling serious illnesses, this product targets hepatitis B. The OTF delivery system enhances the bioavailability of entecavir, making the treatment more effective.
- Aripiprazole OTF - This product is aimed at managing schizophrenia, offering a novel approach to antipsychotic medication administration. Its OTF formulation is designed for ease of use, aiding in the adherence to treatment regimens.
- Montelukast OTF - For patients suffering from asthma and allergic rhinitis, the Montelukast OTF provides a quick and efficient method of medication intake, showcasing the versatility of oral thin film technology in treating a wide range of conditions.
Contact Information
Address: Cheongdam-dong 18-20, #B01
Phone: 82 3 1881 7600
Website: https://www.cmgpharma.co.kr
2026 © Marketlog. All Rights Reserved.
